Allogeneic Stem Cell Transplantation Following Chemotherapy in Patients With Hemoglobinopathies

Phase 2 Completed 2 enrolled Dana-Farber Cancer Institute Beth Israel Deaconess Medical Center · collab Brigham and Women's Hospital · collab Emory University · collab Feist-Weiller Cancer Center at Louisiana State University Health Sciences · collab Massachusetts General Hospital · collab Ohio State University · collab

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine if treatment with reduced-dose busulfex, fludarabine and alemtuzumab (CAMPATH) followed by sten cell infusion will allow for donor stem cells to grow in patients with hemoglobinopathies bone marrow and restore circulating blood counts. In addition the incidence and severity of side effects and of graft vs. host disease (GVHD) will be monitored.

Timeline

Start: 2004-03
Primary completion: 2008-03
Completion: 2009-07

Publications

Results Armistead PM, Mohseni M, Gerwin R, Walsh EC, Iravani M, Chahardouli B, Rostami S, Zhang W, Neuberg D, Rioux J, Ghavamzadeh A, Ritz J, Antin JH, Wu CJ. Erythroid-lineage-specific engraftment in patients with severe hemoglobinopathy following allogeneic hematopoietic stem cell transplantation. Exp Hematol. 2008 Sep;36(9):1205-15. doi: 10.1016/j.exphem.2008.04.004. Epub 2008 Jun 11.

Drugs

Evaluation	Drug	Modality	Dose	Route
Background	Alemtuzumab	Monoclonal antibody	—	Intravenous
Background	Busulfan	Small molecule	—	—
Background	Fludarabine	Small molecule	—	Intravenous

Allogeneic Stem Cell Transplantation Following Chemotherapy in Patients With Hemoglobinopathies

Summary

Timeline

Publications

Drugs

Indications